oncgnostics GmbH

General information
oncgnostics GmbH
Löbstedter Str. 41
07749 Jena, Thuringia

Contact person: Alfred Hansel, Chief Executive Officer
Company main phone: +49 (3641) 5548500
Website:  https://www.oncgnostics.com
Year founded:2012
Source of foundation:Spin-off from public institution / NPO
Name of foundation source:University women's hospital, Jena
Corporate description / mission:
oncgnostics GmbH is specialized in the development of in vitro diagnostic tests for all areas of cancer diagnostics. The company's products are cancer tests that detect characteristic epigenetic changes, i.e. DNA methylations, in cancer cells. These highly informative biomarkers, which they have identified and patented, are the basis of research and development for further IVD tests. The company's GynTect® enables the simple and reliable detection of methylated DNA regions in cervical scrapes. Methylation of GynTect® biomarkers occurs specifically in cervical cancer or its precursors, but not in samples from healthy women. Thus, GynTect® can help to clarify whether there is already a tissue alteration that needs to be treated.
State of ownership: Private / independent
Headquarters: HQ: Yes
  • Biotechnology - R&D Services
  • Diagnostic instrumentation
  • Screening
Primary therapeutic areas:
  • Neoplasms / cancer / oncology
Business model:
  • Manufacturer
  • R&D
  • Service company
Customer segments:
  • Hospitals
  • Large medtech
  • Physicians / doctors
Summary Products / Services / Technologies
Description of products:
GynTect® – assay for cervical cancer screening

The company is developing tests based on DNA methylation markers that detect cancer cells in the patient’s saliva.

The company is also developing patient-friendly screening test could help to significantly reduce the number of deaths caused by ovarian cancer.